

Supplementary Table S1. Univariate analysis of the association of each anti-tuberculosis drug use with treatment success*

	Variable	Drug given	Drug not given	p-value
Bedaquiline	Susceptible strain [†]	131/143 (91.6)	623/790 (78.9)	<0.001
Linezolid	Susceptible strain [†]	201/214 (93.9)	539/701 (76.9)	<0.001
Ofloxacin	Susceptible strain	2/4 (50.0)	149/207 (72.0)	0.334
	Resistant strain	7/9 (77.8)	596/714 (83.5)	0.648
Levofloxacin	Susceptible strain	97/110 (88.2)	129/188 (68.6)	<0.001
	Resistant strain	138/169 (81.7)	390/467 (83.5)	0.582
Moxifloxacin	Susceptible strain	180/209 (86.1)	118/167 (70.7)	<0.001
	Resistant strain	207/241 (85.9)	249/320 (77.8)	0.015
Cycloserine	Susceptible strain	513/595 (86.2)	93/166 (56.0)	<0.001
	Resistant strain	99/115 (86.1)	49/58 (84.5)	0.780
Delamanid	Susceptible strain [†]	90/102 (88.2)	664/832 (79.8)	0.042
Ethambutol	Susceptible strain	181/216 (83.8)	69/119 (58.0)	<0.001
	Resistant strain	246/287 (85.7)	258/312 (82.7)	0.312
Pyrazinamide	Susceptible strain	315/372 (84.7)	71/120 (59.2)	<0.001
	Resistant strain	226/263 (85.9)	142/179 (79.3)	0.068
Streptomycin	Susceptible strain	149/167 (89.2)	318/428 (74.3)	<0.001
	Resistant strain	34/39 (87.2)	253/300 (84.3)	0.643
Amikacin	Susceptible strain	112/124 (90.3)	498/630 (79.0)	<0.001
	Resistant strain	11/16 (68.8)	133/164 (81.1)	0.239
Kanamycin	Susceptible strain	219/237 (92.4)	365/486 (75.1)	<0.001
	Resistant strain	34/43 (79.1)	136/168 (81.0)	0.781
Meropenem	Susceptible strain [†]	32/37 (86.5)	722/897 (80.5)	0.365
Prothionamide	Susceptible strain	410/465 (88.2)	125/206 (60.7)	<0.001
	Resistant strain	117/140 (83.6)	102/123 (82.9)	0.889
Para-aminosalicylic acid	Susceptible strain	206/244 (84.4)	311/420 (74.0)	<0.001
	Resistant strain	61/68 (89.7)	176/202 (87.1)	0.575

Values are presented as number of patients treated successfully/total number of patients (%).

*The comparator is an unfavorable outcome (sum of treatment failure, loss to follow-up and not evaluated). [†]Probable susceptible strain; isolates before 2016 and 2017 were assumed to be susceptible to linezolid and bedaquiline, respectively, and all isolates were assumed to be susceptible to delamanid and meropenem.